← FDA DRUG APPROVALS
FDA ANDA · ANDA218314
SODIUM PHOSPHATES
sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic anhydrous
Sponsor: AM REGENT
APPLICATION
ANDA218314
TYPE
ANDA
ORIGINAL APPROVAL
2024-06-21
LATEST ACTION
2024-06-21
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription
Products
SODIUM PHOSPHATESPrescription
SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE 4.02GM/15ML, SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 4.14GM/15ML (268MG/ML · SOLUTION · INTRAVENOUS
SODIUM PHOSPHATESPrescription
SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE 13.4GM/50ML, SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 13.8GM/50ML (268MG/ML · SOLUTION · INTRAVENOUS
SODIUM PHOSPHATESPrescription
SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE 1.34GM/5ML, SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 1.38GM/5ML (268MG/ML · SOLUTION · INTRAVENOUS
Approval history
2024-06-21UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.